Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Bio Bridge Science (CE) Charts. Click Here for more Bio Bridge Science (CE) Charts.](/p.php?pid=staticchart&s=NO%5EBGES&p=8&t=15)
Bio-Bridge Science Inc. (OTCBB:BGES), a
development-stage biotech company, announced today that its
encouraging results for pharmacological and acute toxicity studies on
its HIV therapeutic Vaccine (HIV-PV pseudovirus) on mice and monkeys
will be a feature in the Corporate News section of Investor's Business
Daily (IBD) today, plus Friday, February 10th and Monday, February
13th. The information is also available online in the "Corporate News"
section of IBD at http://www.investors.com/corporatenews/ for the
next two weeks.
The vaccine, based on exclusive technology co-developed by CEO
Liang Qiao, an associate professor at Loyola University Chicago's
Stritch School of Medicine, targets infection in mucosal tissues, the
first type of tissue attacked by HIV.
Dr. Liang Qiao, Chairman and CEO of Bio-Bridge Science said, "We
are pleased with the initial results of the pre-clinical trials for
our HIV Vaccine. We hope to reach a larger audience of investors
through publishing the information in Investor Business Daily in order
to familiarize them with our company and the exciting technology that
we are testing."
About Bio-Bridge Science
Bio-Bridge Science is a biotechnology firm focused on the
development of vaccines with broad therapeutic and preventive
applications. Through its wholly owned subsidiary in Beijing,
Bio-Bridge is developing a promising new HIV Vaccine, that is expected
to enter clinical trials in China in the very near future. The
vaccine, based on exclusive technology co-developed by CEO Liang Qiao,
an associate professor at Loyola University Chicago's Stritch School
of Medicine, targets infection in mucosal tissues, the first type of
tissue attacked by HIV.
The Chinese government, mindful of the rapid expansion of AIDS in
China has, through the "Green Mile Policy," acted to expedite the
approval of domestically produced HIV Vaccines and has dramatically
increased its spending on AIDS-related research. In accordance with
this policy, Bio-Bridge expects to bring its therapeutic HIV Vaccine
to market as early as 2008, far in advance of many other HIV Vaccines
currently in development. Bio-Bridge is currently constructing a new
$3 million state-of-the-art GMP research and manufacturing facility in
Beijing, which is expected to be completed in early 2006.
Forward-Looking Statements
This press release contains forward-looking statements as defined
by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to
uncertainties and risks including, but not limited to, product and
service demand and acceptance, changes in technology, economic
conditions, the impact of competition and pricing, government
regulation, and other risks defined in this document and in statements
filed from time to time with the Securities and Exchange Commission.
All such forward-looking statements, whether written or oral, and
whether made by or on behalf of the company, are expressly qualified
by these cautionary statements and any other cautionary statements
which may accompany the forward-looking statements. In addition, the
company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date hereof.
Please refer to SEC filings for additional information and
accompanying notes to financial statements.